The Bio-inflammation Company

Transforming Human Health Through The Restoration Of Ammonia-Oxidizing Bacteria

An evolutionary approach to restoring health

AOBiome Therapeutics is a clinical-stage therapeutics company addressing a broad range of inflammatory conditions by harnessing a single strain of class defining
Ammonia Oxidizing Bacteria (AOB).

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

Learn More

AOBiome currently has multiple
Phase 2 clinical programs

AOBiome currently has Phase 2 clinical programs in hypertension, acne, allergic rhinitis, migraine, eczema and rosacea.

Learn More

Committed to transforming & improving human health

We believe that the restoration of the symbiotic relationship between bacteria and humans
will have a profound impact on human health.

Clinical Trials

Science

Manufacturing

About

In the News

June 30, 2020 · Cambridge, MA

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

April 29, 2019 · Cambridge, MA

AOBiome Featured on NPR’s Marketplace

April 22, 2019 · Cambridge, MA

AOBiome Featured in Bloomberg Businessweek

The Bio-inflammation Company

An evolutionary approach to restoring health

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

AOBiome currently has multiple Phase 2 clinical programs

AOBiome currently has Phase 2 clinical programs in hypertension, acne, allergic rhinitis, migraine, eczema and rosacea.

Committed to transforming & improving human health

AOBiome currently has multiple
Phase 2 clinical programs